Search results
Results from the WOW.Com Content Network
A feedback loop involving erythropoietin helps regulate the process of erythropoiesis so that, in non-disease states, the production of red blood cells is equal to the destruction of red blood cells and the red blood cell number is sufficient to sustain adequate tissue oxygen levels but not so high as to cause sludging, thrombosis, or stroke ...
Erythropoietin (/ ɪ ˌ r ɪ θ r oʊ ˈ p ɔɪ. ɪ t ɪ n,-r ə-,-p ɔɪ ˈ ɛ t ɪ n,-ˈ iː t ɪ n /; [1] [2] [3] EPO), also known as erythropoetin, haematopoietin, or haemopoietin, is a glycoprotein cytokine secreted mainly by the kidneys in response to cellular hypoxia; it stimulates red blood cell production (erythropoiesis) in the bone marrow.
The 2020 Cochrane Anaesthesia Review Group review of erythropoietin (EPO) plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing non‐cardiac surgery [11] demonstrated that patients were much less likely to require red cell transfusion and in those transfused, the volumes were unchanged (mean ...
Ineffective erythropoiesis is defined by the expansion of early-stage erythroid precursors driven by erythropoietin, accompanied by the apoptosis of late-stage precursors. . This mechanism is principally responsible for the anemia seen in acquired conditions such as certain subtypes of myelodysplastic syndrome (MDS) and inherited disorders such as β-thalassemia, inherited sideroblastic ...
Epoetin alfa, sold under the brand name Epogen among others, is a human erythropoietin produced in cell culture using recombinant DNA technology. [8] [9] Epoetin alfa is an erythropoiesis-stimulating agent. [8]
Erythropoietin is a sialoglycoprotein hormone produced by peritubular cells of kidney. Granulocyte -macrophage colony-stimulating factor and granulocyte CSF are given to stimulate white blood cell formation in cancer patients who are receiving chemotherapy , which tends to kill their red bone marrow cells as well as the cancer cells.
Continuous erythropoietin receptor activator (CERA) is the generic term for drugs in a new class of third-generation erythropoiesis-stimulating agents (ESAs). In the media, these agents are commonly referred to as 'EPO', short for erythropoietin .
Erythropoietin in neuroprotection is the use of the glycoprotein erythropoietin (Epo) for neuroprotection. Epo controls erythropoiesis , or red blood cell production. Erythropoietin and its receptor were thought to be present in the central nervous system according to experiments with antibodies that were subsequently shown to be nonspecific.